Biogen (BIIB) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization in the European Union for Zurzuvae to treat postpartum depression.
Biogen and Sage Therapeutics (SAGE), which discovered Zurzuvae, agreed in 2020 to jointly develop and commercialize Zurzuvae in the US. Under the deal, Biogen has exclusive rights to develop and commercialize Zurzuvae outside of the U.S., excluding Japan, Taiwan, and South Korea.
Biogen said the recommendation for Zurzuvae will now be reviewed by the European Commission for marketing authorization in the European Union. It said it expects a decision to be made in Q3.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。